Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018

Jan 23 2018

• By Michael Cipriano

Pipeline — This is the actual pipeline sponsors use to get their applcaitions to FDA.

Related Content

CDER's 2017 New Drug Class Maintains Steady Innovative Composition With Recent Years

Jan 04 2018

Keeping Track: New MCL Treatment Calquence, Submissions Galore, And A Breakthrough Designation For GSK

Nov 03 2017

Keeping Track: A Massive Week Of Agency Approvals

Nov 13 2017

FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week

Dec 22 2017

Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris

Oct 30 2017

Response Rates Rule In CGRP Inhibitor Migraine Studies

Jun 12 2017

Another Antibiotic Success Story as Tetraphase's Eravacycline Meets Goal

Jul 26 2017

Related Companies

Amgen, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

Alnylam Pharmaceuticals Inc.

Ionis Pharmaceuticals, Inc.

GW Pharmaceuticals plc

Portola Pharmaceuticals, Inc.

Bayer AG

Liminal BioSciences Inc.

Akcea Therapeutics, Inc.

Amicus Therapeutics, Inc.

Achaogen, Inc.

Tetraphase Pharmaceuticals, Inc.

Trevena Inc.

Additional Topics

United States Drug Review FDA Regulation Neurology BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window